

## ICMJE DISCLOSURE FORM

**Date:** 05 July 2022

**Your Name:** Makoto Nishio

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca	Grant and personal fees
		Amgen	Grant and personal fees
		MSD	Grant and personal fees
		Taiho Pharmaceutical	Grant and personal fees
		Takeda Pharmaceutical	Grant and personal fees
		Chugai Pharmaceutical	Grant and personal fees
		Eli Lilly	Grant and personal fees
		Novartis	Grant and personal fees

		Pfizer	Grant and personal fees
		Bristol-Myers Squibb	Grant and personal fees
		Merck Biopharma	Grant and personal fees
		Daiichi-Sankyo	Grant
3	Royalties or licenses	(X) None	
4	Consulting fees	(X) None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	(X) None	
6	Payment for expert testimony	(X) None	
7	Support for attending meetings and/or travel	(X) None	
8	Patents planned, issued or pending	(X) None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	(X) None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	(X) None	
11	Stock or stock options	(X) None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	(X) None	
13	Other financial or non-financial interests	Ono Pharmaceutical	Personal fees
		Boehringer Ingelheim	Personal fees
		Janssen Pharmaceutical	Personal fees

**Please summarize the above conflict of interest in the following box:**

Received funding from Chugai Pharmaceutical for medical writing support and payment of article processing charges; grants and personal fees from AstraZeneca, Amgen, MSD, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Novartis, Pfizer, Bristol-Myers Squibb, and Merck Biopharma; personal fees from Ono Pharmaceutical, Boehringer Ingelheim, and Janssen Pharmaceutical; and grants from Daiichi-Sankyo.

**Please place an "X" next to the following statement to indicate your agreement:**

**[X] I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 04 July 2022

**Your Name:** Shinji Atagi

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Institutional
		Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca	Grant (institutional)
		Eli Lilly	Grant (institutional)
		Ono	Grant (institutional)
		Taiho Pharmaceutical	Grant (institutional)

		Boehringer Ingelheim	Grant (institutional)
		Pfizer	Grant (institutional)
		Bristol-Myers Squibb	Grant (institutional)
		MSD	Grant (institutional)
		Chugai Pharmaceutical	Grant (institutional)
		Merck	Grant (institutional)
		F. Hoffmann-La Roche	Grant (institutional)
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical	Honoraria (personal)
		Eli Lilly	Honoraria (personal)
		Taiho Pharmaceutical	Honoraria (personal)
		Sawai Pharmaceutical	Honoraria (personal)
		Novartis Pharma	Honoraria (personal)
		AstraZeneca	Honoraria (personal)
		Ono	Honoraria (personal)
		Boehringer Ingelheim	Honoraria (personal)
		Pfizer	Honoraria (personal)
		Bristol-Myers Squibb	Honoraria (personal)
		Hisamitsu	Honoraria (personal)
		MSD	Honoraria (personal)
		Kyowa Hakko Kirin	Honoraria (personal)
		Merck	Honoraria (personal)
		Thermo Fisher Scientific	Honoraria (personal)
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment,	<input checked="" type="checkbox"/> None	

	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received funding from Chugai Pharmaceutical.  
 Received grants from AstraZeneca, Eli Lilly, Ono, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, MSD, Chugai Pharmaceutical, Merck, and F. Hoffmann-La Roche.  
 Received honoraria from Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, Sawai Pharmaceutical, Novartis Pharma, AstraZeneca, Ono, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Hisamitsu, MSD, Kyowa Hakko Kirin, Merck, and Thermo Fisher Scientific.

**Please place an “X” next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 29 June 2022

**Your Name:** Koichi Goto

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical Co., Ltd.	Institution/myself
		Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Amgen Astellas BioPharma	Research grant
		Amgen	Research grant
		AstraZeneca	Research grant
		Bayer Yakuhin, Ltd.	Research grant
		Bristol-Myers Squibb K.K.	Research grant
		Boehringer Ingelheim Japan, Inc.	Research grant

		Blueprint Medicines Corporation	Research grant
		DAIICHI SANKYO Co., Ltd.	Research grant
		Eisai Co., Ltd.	Research grant
		Eli Lilly Japan K.K.	Research grant
		Haihe Biopharma Co., Ltd.	Research grant
		Ignyta, Inc.	Research grant
		Janssen Pharmaceutical K.K.	Research grant
		KISSEI PHARMACEUTICAL CO., LTD.	Research grant
		Kyowa Kirin Co., Ltd.	Research grant
		Life Technologies Japan Ltd.	Research grant
		Loxo Oncology, Inc.	Research grant
		MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.	Research grant
		Merck Biopharma Co., Ltd.	Research grant
		Merus N.V.	Research grant
		MSD K.K.	Research grant
		NEC Corporation	Research grant
		Novartis Pharma K.K.	Research grant
		Ono Pharmaceutical Co., Ltd.	Research grant
		Pfizer Japan Inc.	Research grant
		Sumitomo Dainippon Pharma Co., Ltd.	Research grant
		Spectrum Pharmaceuticals, Inc.	Research grant
		Sysmex Corporation	Research grant
		Taiho Pharmaceutical Co., Ltd.	Research grant
		Takeda Pharmaceutical Co., Ltd.	Research grant
		Turning Point Therapeutics, Inc.	Research grant
3	Royalties or licenses	(X) None	
4	Consulting fees	(X) None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Amgen Inc.	Honoraria
		AstraZeneca K.K.	Honoraria
		Bayer HealthCare Pharmaceuticals Inc.,	Honoraria
		Boehringer Ingelheim Japan Inc.	Honoraria
		Bristol-Myers Squibb K.K.	Honoraria
		DAIICHI SANKYO Co., Ltd.	Honoraria
		Eisai Co., Ltd.	Honoraria
		Eli Lilly Japan K.K.	Honoraria
		Guardant Health Inc.	Honoraria
		Janssen Pharmaceutical K.K.	Honoraria
		Kyowa Kirin Co., Ltd.	Honoraria
		Life Technologies Japan Ltd.	Honoraria
		Medpace Japan K.K.	Honoraria
		Merck Biopharma Co., Ltd.	Honoraria
		MSD K.K.	Honoraria
		Novartis Pharma K.K.	Honoraria
		Ono Pharmaceutical Co., Ltd.	Honoraria
		Otsuka Pharmaceutical Co., Ltd.	Honoraria

		Pfizer Japan Inc.	Honoraria
		Taiho Pharmaceutical Co., Ltd.	Honoraria
		Takeda Pharmaceutical Co., Ltd.	Honoraria
6	Payment for expert testimony	(X) None	
7	Support for attending meetings and/or travel	(X) None	
8	Patents planned, issued or pending	(X) None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	(X) None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	(X) None	
11	Stock or stock options	(X) None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	(X) None	
13	Other financial or non-financial interests	(X) None	

**Please summarize the above conflict of interest in the following box:**

All support for the present manuscript from Chugai Pharmaceutical Co., Ltd., :Received research grants from Amgen Astellas BioPharma, Amgen, AstraZeneca, Bayer Yakuhin, Ltd., Bristol-Myers Squibb K.K., Boehringer Ingelheim Japan, Inc., Blueprint Medicines Corporation, DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., Ignyta, Inc., Janssen Pharmaceutical K.K., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Life Technologies Japan Ltd., Loxo Oncology, Inc., MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., Merck Biopharma Co., Ltd., Merus N.V., MSD K.K., NEC Corporation, Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sumitomo Dainippon Pharma Co., Ltd., Spectrum Pharmaceuticals, Inc., Sysmex Corporation, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Turning Point Therapeutics, Inc. ; honoraria from Amgen Inc., AstraZeneca K.K., Bayer HealthCare Pharmaceuticals Inc., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Guardant Health Inc., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Life Technologies Japan Ltd., Medpace Japan K.K., Merck Biopharma Co., Ltd., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd.

**Please place an “X” next to the following statement to indicate your agreement:**

**[X] I certify that I have answered every question and have not altered the wording of any of the questions on this form.**



## ICMJE DISCLOSURE FORM

**Date:** 29 June 2022

**Your Name:** Yukio Hosomi

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical	Payment/honoraria
		AstraZeneca	Payment/honoraria
		Eli Lilly Japan	Payment/honoraria
		Taiho Pharmaceutical	Payment/honoraria
		Bristol-Myers Squibb	Payment/honoraria
		Kyowa Kirin	Payment/honoraria
		Ono Pharmaceutical	Payment/honoraria
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received payment/honoraria from Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin, and Ono Pharmaceutical.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 07 July 2022

**Your Name:** Takashi Seto

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AbbVie	Institution
		Chugai Pharmaceutical	Institution
		Daiichi-Sankyo	Institution
		Eli Lilly Japan	Institution

		Kissei Pharmaceutical	Institution
		MSD	Institution
		Novartis Pharma	Institution
		Pfizer Japan	Institution
		Takeda Pharmaceutical	Institution
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca	Honoraria for lectures
		Bristol-Myers Squibb	Honoraria for lectures
		Chugai Pharmaceutical	Honoraria for lectures
		Covidien Japan	Honoraria for lectures
		Daiichi Sankyo	Honoraria for lectures
		Eli Lilly Japan	Honoraria for lectures
		Kyowa Hakko Kirin	Honoraria for lectures
		MSD	Honoraria for lectures
		Mochida Pharmaceutical	Honoraria for lectures
		Nippon Boehringer Ingelheim	Honoraria for lectures
		Novartis Pharma	Honoraria for lectures
		Ono Pharmaceutical	Honoraria for lectures
		Pfizer Japan	Honoraria for lectures
		Taiho Pharmaceutical	Honoraria for lectures
		Takeda Pharmaceutical	Honoraria for lectures
		Towa Pharmaceutical	Honoraria for lectures
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment,	<input checked="" type="checkbox"/> None	

	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	Precision Medicine Asia	Employment

**Please summarize the above conflict of interest in the following box:**

Received funding from AbbVie, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, MSD, Novartis Pharma, Pfizer Japan, Takeda Pharmaceutica (Institution) and honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Covidien Japan, Daiichi Sankyo, Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Mochida Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, Takeda Pharmaceutical, Towa Pharmaceutical .  
 Other: Precision Medicine Asia(employment)

**[X] I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 29 June 2022

**Your Name:** Toyoaki Hida

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Chugai Pharmaceutical	Research grant
		AstraZeneca	Research grant
		Nippon Boehringer	Research grant
		Ingelheim	

		Pfizer	Research grant
		Eli Lilly	Research grant
		Takeda Bio	Research grant
		Novartis Pharma	Research grant
		Ono Pharmaceutical	Research grant
		Daiichi-Sankyo	Research grant
		Merck Serono	Research grant
		Dainippon Sumitomo Pharma	Research grant
		Bristol-Myers Squibb	Research grant
		Eisai	Research grant
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received research grants from Chugai Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Eli Lilly, Takeda Bio, Novartis Pharma, Ono Pharmaceutical, Daiichi-Sankyo, Merck Serono, Dainippon Sumitomo Pharma, Bristol-Myers Squibb, and Eisai.

**Please place an “X” next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**



## ICMJE DISCLOSURE FORM

**Date:** 01 July 2022

**Your Name:** Kazuhiko Nakagawa

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical	Honoraria
		AstraZeneca	Honoraria
		Nippon Boehringer Ingelheim	Honoraria
		Eli Lilly	Honoraria
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received honoraria from Chugai Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, and Eli Lilly.

**Please place an "X" next to the following statement to indicate your agreement:**

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 28 June 2022

**Your Name:** Hiroshige Yoshioka

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Chugai Pharmaceutical	Research grant
		Boehringer Ingelheim	Research grant
		Nippon Kayaku	Research grant
3	Royalties or licenses	<input checked="" type="checkbox"/> None	

4	Consulting fees	Delta Fly Pharma	Consulting fees
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Eli Lilly	Honoraria
		Chugai Pharmaceutical	Honoraria
		Boehringer Ingelheim	Honoraria
		Delta Fly Pharma	Honoraria
		AstraZeneca	Honoraria
		BMS	Honoraria
		MSD	Honoraria
		Ono Pharmaceutical	Honoraria
		Merck Biopharma	Honoraria
		Nippon Kayaku	Honoraria
		Taiho Pharmaceutical	Honoraria
		Otsuka Pharmaceutical	Honoraria
		Takeda Pharmaceutical	Honoraria
		Novartis Pharmaceutical	Honoraria
		Amgen	Honoraria
		Nipro Pharma	Honoraria
		Kyowa Kirin	Honoraria
		Pfizer	Honoraria
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

--	--	--	--

**Please summarize the above conflict of interest in the following box:**

Research grants from Chugai Pharmaceutical, Boehringer Ingelheim and Nippon Kayaku; Consulting fees from Delta Fly Pharma; honoraria from Eli Lilly, Chugai Pharmaceutical, Boehringer Ingelheim, Delta Fly Pharma, AstraZeneca, BMS, MSD, Ono Pharmaceutical, Merck Biopharma, Nippon Kayaku, Taiho Pharmaceutical, Otsuka Pharmaceutical, Takeda Pharmaceutical, Novartis Pharmaceutical, Amgen, Nipro Pharma, Kyowa Kirin, and Pfizer.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 05 July 2022

**Your Name:** Naoyuki Nogami

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	(X) None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical	Honoraria
		Pfizer Japan	Honoraria
		Taiho Pharmaceutical	Honoraria
		Daiichi-Sankyo	Honoraria
		Eli Lilly Japan	Honoraria
		AstraZeneca	Honoraria
		Nippon Boehringer Ingelheim	Honoraria
6	Payment for expert testimony	(X) None	
7	Support for attending meetings and/or travel	(X) None	
8	Patents planned, issued or pending	(X) None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	(X) None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	(X) None	
11	Stock or stock options	(X) None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	(X) None	
13	Other financial or non-financial interests	(X) None	

**Please summarize the above conflict of interest in the following box:**

Received honoraria from Chugai Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, Daiichi-Sankyo, Eli Lilly Japan, AstraZeneca, and Nippon Boehringer Ingelheim.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.



## ICMJE DISCLOSURE FORM

**Date:** 27 May 2022

**Your Name:** Makoto Maemondo

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Nippon Boehringer Ingelheim	Research grant

3	Royalties or licenses	(X) None	
4	Consulting fees	(X) None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical AstraZeneca Nippon Boehringer Ingelheim	Honoraria Honoraria Honoraria
6	Payment for expert testimony	(X) None	
7	Support for attending meetings and/or travel	(X) None	
8	Patents planned, issued or pending	(X) None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	(X) None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	(X) None	
11	Stock or stock options	(X) None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	(X) None	
13	Other financial or non-financial interests	(X) None	

**Please summarize the above conflict of interest in the following box:**

Received honoraria from Chugai Pharmaceutical and AstraZeneca; research grants and honoraria from Nippon Boehringer Ingelheim.

**Please place an "X" next to the following statement to indicate your agreement:**

**[X] I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 13 July 2022

**Your Name:** Seisuke Nagase

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

No personal conflict of interests to disclose.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 05 July 2022

**Your Name:** Isamu Okamoto

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical	Payment/honoraria
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received payment/honoraria from Chugai Pharmaceutical.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 28 June 2022

**Your Name:** Noboru Yamamoto

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Chugai Pharmaceutical	Research grant
		Taiho Pharmaceutical	Research grant
		Eisai	Research grant
		Eli Lilly	Research grant

		Quintiles	Research grant
		Astellas Pharma	Research grant
		Bristol-Myers Squibb	Research grant
		Novartis	Research grant
		Daiichi-Sankyo	Research grant
		Pfizer	Research grant
		Boehringer Ingelheim	Research grant
		Kyowa-Hakko Kirin	Research grant
		Bayer	Research grant
		Ono Pharmaceutical Co. Ltd	Research grant
		Takeda	Research grant
		Janssen Pharma	Research grant
		MSD	Research grant
		Merck	Research grant
		GSK	Research grant
		Sumitomo Dainippon	Research grant
		Chiome Bioscience Inc.	Research grant
		Otsuka	Research grant
		Carna Biosciences	Research grant
		Genmab	Research grant
		Shionogi	Research grant
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	Eisai	Personal fees
		Otsuka	Personal fees
		Takeda	Personal fees
		Boehringer Ingelheim	Personal fees
		Cimic	Personal fees
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Ono Pharmaceutical	Honoraria (personal fees)
		Chugai Pharmaceutical	Honoraria (personal fees)
		AstraZeneca	Honoraria (personal fees)
		Pfizer	Honoraria (personal fees)
		Eli Lilly	Honoraria (personal fees)
		Bristol-Myers Squibb	Honoraria (personal fees)
		Sysmex	Honoraria (personal fees)
		Eisai	Honoraria (personal fees)
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data	<input checked="" type="checkbox"/> None	



	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received research grants from Chugai Pharmaceutical, Taiho Pharmaceutical, Eisai, Eli Lilly, Quintiles, Astellas Pharma, Bristol-Myers Squibb, Novartis, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Bayer, Ono Pharmaceutical Co. Ltd, Takeda, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience Inc, Otsuka, Carina Biosciences, Genmab, and Shionogi; honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Systemex, and Eisai; and consulting fees from Eisai, Otsuka, Takeda, Boehringer Ingelheim, and Cimic.

**Please place an “X” next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 29 June 2022

**Your Name:** Yuriko Igawa

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	(X) None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	(X) None	
6	Payment for expert testimony	(X) None	
7	Support for attending meetings and/or travel	(X) None	
8	Patents planned, issued or pending	(X) None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	(X) None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	(X) None	
11	Stock or stock options	(X) None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	(X) None	
13	Other financial or non-financial interests	Chugai Pharmaceutical	Employment

**Please summarize the above conflict of interest in the following box:**

Employee of Chugai Pharmaceutical.

**Please place an "X" next to the following statement to indicate your agreement:**

**[X] I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 29 June 2022

**Your Name:** Kosei Tajima

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	Chugai Pharmaceutical	Employment

**Please summarize the above conflict of interest in the following box:**

Employee of Chugai Pharmaceutical.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 21 July 2022

**Your Name:** Masahiro Fukuoka

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(X) None	
3	Royalties or licenses	(X) None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Eisai Chugai Pharmaceutical	Honoraria Honoraria
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received honoraria from Eisai and Chugai Pharmaceutical.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

**Date:** 29 June 2022

**Your Name:** Nobuyuki Yamamoto

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai	My institution
		Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	MSD K.K.	My institution
		AstraZeneca	My institution
		ONO PHARMACEUTICAL CO., LTD.	My institution



		DAIICHI SANKYO CO., LTD.	My institution
		TAIHO PHARMACEUTICAL CO., LTD.	My institution
		Takeda Pharmaceutical CO., LTD.	My institution
		Chugai Pharmaceutical CO., LTD.	My institution
		Pfizer Inc.	My institution
		Amgen Inc.	My institution
		Janssen Pharmaceutical K.K.	My institution
		Toppan printing	My institution
		Terumo	My institution
		Boehringer Ingelheim	My institution
3	Royalties or licenses	(X) None	
4	Consulting fees	AstraZeneca	Me
		DAIICHI SANKYO CO., LTD.	Me
		TAIHO PHARMACEUTICAL CO., LTD.	Me
		Takeda Pharmaceutical CO., LTD.	Me
		Chugai Pharmaceutical CO., LTD.	Me
		Eli Lilly Japan K.K.	Me
		Boehringer Ingelheim	Me
		Novartis	Me
		Bristol-Myers Squibb	Me
		NIPPON KAYAKU	Me
		Life Technologies Japan Ltd.	Me
		Amgen Inc.	Me
		Guardant Health Japan	Me
		Janssen Pharmaceutical K.K.	Me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	MSD	Honoraria
		AstraZeneca	Honoraria
		Ono Pharmaceutical	Honoraria
		Thermo Fisher Scientific	Honoraria
		Daiichi-Sankyo	Honoraria
		Taiho Pharmaceutical co., Ltd.	
		Takeda Pharmaceutical Co., Ltd	Honoraria
		Chugai Pharmaceutical	Honoraria
		Eli Lilly Japan K.K.	Honoraria
		Boehringer Ingelheim	Honoraria
		Novartis	Honoraria
		Pfizer Inc.	Honoraria
		Bristol-Myers Squibb	Honoraria

		NIPPON KAYAKU	Honoraria
		GSK K.K.	Honoraria
		Sanofi K.K.	Honoraria
		Hisamitsu Pharmaceutical Co., Inc.	Honoraria
		Merck Biopharma	Honoraria
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	MSD K.K.	Data safety monitoring board/advisory board
		AstraZeneca	Data safety monitoring board/advisory board
		Ono Pharmaceutical Co. Ltd	Data safety monitoring board/advisory board
		Takeda Pharmaceutical Co. Ltd	Data safety monitoring board/advisory board
		Chugai Pharmaceutical Co. Ltd.	Data safety monitoring board/advisory board
		Eli Lilly Japan K.K.	Data safety monitoring board/advisory board
		Boehringer Ingelheim	Data safety monitoring board/advisory board
		Pfizer Inc.	Data safety monitoring board/advisory board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Received honoraria from MSD K.K., AstraZeneca, Ono Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Taiho Pharmaceutical., Takeda, Chugai Pharmaceutical Co., Ltd., Pfizer, Amgen, Janssen Pharmaceutical K.K., Toppan printing, Terumo, and Boehringer Ingelheim; consulting fees from AstraZeneca, Daiichi-Sankyo, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Boehringer Ingelheim, Novartis, Bristol-Myers Squibb, NIPPON KAYAKU, Life Technologies Japan, Ltd., Amgen, Guardant Health Japan, and Janssen Pharmaceutical K.K.; honoraria from MSD, AstraZeneca, Ono Pharmaceutical, Thermo Fisher Scientific, Daiichi-Sankyo, Taiho Pharmaceutical, Takeda, Chugai Pharmaceutical, Eli Lilly Japan K.K., Boehringer Ingelheim, Novartis, Pfizer, Bristol-Myers Squibb, NIPPON KAYAKU, GSK K.K., Sanofi K.K., Hisamitsu Pharmaceutical, and Merck Biopharma; and participated on a data safety monitoring board/advisory board for MSD K.K., AstraZeneca, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan K.K., Boehringer Ingelheim, and Pfizer

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 05 July 2022

**Your Name:** Kazuto Nishio

**Manuscript Title:** Biomarker Analysis of the Phase II JO25567 Study Comparing Erlotinib With or Without Bevacizumab in First-Line Advanced *EGFR+* NSCLC

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Chugai Pharmaceutical	Funding for medical writing support; payment of article processing charges
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Nippon Boehringer Ingelheim	
		West Japan Oncology Group	

		Thoracic Oncology Research Group	
		North East Japan Study Group	
		Clinical Research Support Center Kyushu	
		Nichirei Biosciences Inc.	
		Eli Lilly Japan	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	SymBio Pharmaceuticals	
		Solasia Pharma	
		ELI LILLY JAPAN	
		Otsuka Pharmaceutical	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Boehringer Ingelheim Japan	Honoraria for lectures
		AstraZeneca	Honoraria for lectures
		Chugai	Honoraria for lectures
		Novartis Pharma	Honoraria for lectures
		Eisai	Honoraria for lectures
		MSD	Honoraria for lectures
		Bristol-Myers Squibb	Honoraria for lectures
		Ono Pharmaceutical	Honoraria for lectures
		Pfizer	Honoraria for lectures
		Sanofi	Honoraria for lectures
		Guardant Health	Honoraria for lectures
		ELI LILLY JAPAN.	Honoraria for lectures
		Amgen	Honoraria for lectures
		Merck Biopharma	Honoraria for lectures
		Roche Diagnostics	Honoraria for lectures
		Yakult Honsha	Honoraria for lectures
		Takeda Pharmaceutical	Honoraria for lectures
		FUJIREBIO	Honoraria for lectures
		Janssen Pharmaceutical	Honoraria for lectures
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role	<input checked="" type="checkbox"/> None	

	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

Grants from Nippon Boehringer Ingelheim, West Japan Oncology Group, Thoracic Oncology Research Group, North East Japan Study Group, Clinical Research Support Center Kyushu, Nichirei Biosciences Inc., Eli Lilly Japan, Consulting fees from Symbio Pharmaceuticals, Solasia Pharma, ELI LILLY JAPAN, Otsuka Pharmaceutical, honoraria for lectures from Boehringer Ingelheim Japan, AstraZeneca, Chugai, Novartis Pharma, Eisai, MSD, Bristol-Myers Squibb, Ono Pharmaceutical, Pfizer, Sanofi, Guardant Health, ELI LILLY JAPAN, Amgen, Merck Biopharma, Roche Diagnostics, Yakult Honsha, Takeda pharmaceuticals, FUJIREBIO, Janssen Pharmaceutical.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**